Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress

WOBURN, Mass., Oct. 18, 2011 /PRNewswire/ -- CBI is pleased to announce the full agenda for CMAC 2011 - CBI's 2nd Annual Commercialization and Market Access Congress, being held December 6-7, 2011 in Philadelphia, PA. The program, sponsored by Campbell Alliance and McKesson Specialty Care Solutions, delivers pre- and post-launch strategies, dynamic programming and extensive coverage of market access trends.

Anchored by conference chairman, Robert Besthof, Vice President, Commercial Lead, ERP U.S. & Puerto Rico, Pfizer Inc., CMAC 2011 boasts an impressive speaker lineup from AstraZeneca, Baxter, Bristol-Myers Squibb, Daiichi Sankyo, Endo, Eli Lilly, ImClone, InterMune, Metamark Genetics, Grifols, ISTA Pharmaceuticals, Shire, Vertex and many more. Attendees have the opportunity to customize their congress by choosing between workshops, pre- and post-launch tracks and participating in interactive panel discussions. Session highlights include:

  • Product Commercialization Simulation from Candidate Selection through Launch
  • Reimbursement Strategies to Ensure Favorable Coverage, Coding and Payment Decisions
  • The Emergence of Personalized Medicine
  • Global Rollout
  • Brand Commercialization in a Crowded Therapeutic Marketplace
  • Building Specialty Launch Teams
  • Re-Positioning Products Post-Launch
  • KOL Engagement to Optimize Commercialization Efforts

CMAC 2011 is the industry's only opportunity to participate in an executive-level exchange addressing the overarching product development and launch environment, as well as tactical approaches for pricing, reimbursement, product launch, commercial strategy, branding, managed care and HEOR. For more information on the conference or to view the entire agenda, please visit http://www.cbinet.com/cmac2011.  

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact: Emily Forest, Marketing Manager, at 339-298-2156.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE CBI

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.